Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 2Gliosarcoma 2Glioma 2Glioblastoma 2Breast Neoplasms 2Brain Neoplasms 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Medulloblastoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Breast Neoplasms, Male 1Adenocarcinoma 1

Interventions

Radiotherapy 5Temozolomide 4Radiation 3Irinotecan 3Bevacizumab 3ribociclib 2abemaciclib 2Vorinostat 2Mebendazole 2Everolimus 2Dasatinib 2vandetanib 1temsirolimus 1sargramostim 1reolysin 1pembrolizumab 1ovex 1nimotuzumab 1irinotecan sucrosofate 1dinutuximab 1crenolanib 1adavosertib 1Vincristine 1Valproic Acid 1Sirolimus 1Re-Irradiation 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Radiation Dose Hypofractionation 1Piperazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Diffuse Intrinsic Pontine Glioma × 1-methyltryptophan × Clear all
NCT02502708 2020-06-04

Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors

Lumos Pharma

Phase 1 Completed
81 enrolled
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡